{
    "clinical_study": {
        "@rank": "13206", 
        "arm_group": {
            "arm_group_label": "Fat Reduction", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate if multiple same-day CoolSculpting treatments increase the risk of abnormal\n      lipids and liver-related tests."
        }, 
        "brief_title": "Multiple Treatment Study", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Body Fat Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Sphingolipidoses", 
                "Lipid Metabolism Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Male or female subjects > 18 years of age.\n\n          -  Subject who has been assessed to receive multiple CoolSculpting treatments on the\n             abdomen and flanks, defined as follows:\n\n               1. Lower Abdomen - One 60 minute cycle with CoolMax,\n\n               2. Right and Left Flank - One 60 minute cycle per flank, with CoolCurve+ or\n                  CoolCore, simultaneously.\n\n          -  Subject has not had weight change exceeding 10 pounds in the preceding month.\n\n          -  Subject with body mass index (BMI) up to 30. BMI is defined as weight in pounds\n             multiplied by 703 divided by the square of the height in inches.\n\n          -  Subject agrees to not making any major changes in their diet or lifestyle during the\n             course of the study.\n\n          -  Subject has read and signed a written informed consent form.\n\n        Exclusion Criteria\n\n          -  Subject has had an invasive (e.g., liposuction, mesotherapy, abdominoplasty) or\n             non-invasive fat reduction and/or body contouring procedure in the area of intended\n             treatment within the past 6 months.\n\n          -  Subject needs to administer, or has a known history of subcutaneous injections into\n             the area of intended treatment (e.g., heparin, insulin) within the past month.\n\n          -  Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold\n             hemoglobinuria.\n\n          -  Subject has a history of hernia in the area(s) to be treated.\n\n          -  Subject is pregnant or intending to become pregnant during the study period (in the\n             next 4 months).\n\n          -  Subject is lactating or has been lactating during the past 3 months.\n\n          -  Subject is unable or unwilling to comply with the study requirements, such as blood\n             draw.\n\n          -  Subject is currently enrolled in a clinical study of any other unapproved\n             investigational drug or device.\n\n          -  Subject has a history of lipodosis or other confounding metabolic diseases.\n\n          -  Subject is taking or has taken medication within the past 3 months which may affect\n             the metabolic function.\n\n          -  Patient has a history of diabetes.\n\n          -  Any other condition or laboratory value that would, in the professional opinion of\n             the investigator, potentially affect the subject's response or the integrity of the\n             data or would pose an unacceptable risk to the subject."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814007", 
            "org_study_id": "ZA13-001"
        }, 
        "intervention": {
            "arm_group_label": "Fat Reduction", 
            "description": "Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.", 
            "intervention_name": "The Zeltiq System", 
            "intervention_type": "Device", 
            "other_name": [
                "Cryolipolysis", 
                "Lipolysis"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lipolysis", 
            "Cryolipolysis", 
            "Fat Reduction"
        ], 
        "lastchanged_date": "May 16, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Pleasanton", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94588"
                    }, 
                    "name": "Innovation Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Walnut Creek", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94598"
                    }, 
                    "name": "Ed Becker, MD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33133"
                    }, 
                    "name": "Bowes Dermatology Group"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "SAFETY EVALUATION OF MULTIPLE COOLSCULPTING TREATMENTS", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood draws will be collected at various intervals, after the multiple treatments have been performed, and analyzed.", 
            "measure": "Evaluation of lipid levels", 
            "safety_issue": "No", 
            "time_frame": "12-weeks post treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814007"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Incidence and severity of all reported adverse events and clinical assessment of any side effects/pain in the treatment area.", 
            "measure": "Safety", 
            "safety_issue": "No", 
            "time_frame": "12 weeks post treatment"
        }, 
        "source": "Zeltiq Aesthetics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zeltiq Aesthetics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}